Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(4):255-257; doi:10.1093/jnci/95.4.255
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Goldman, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldman, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 4, 255-257, February 19, 2003
© 2003 Oxford University Press

NEWS

Multidrug Resistance: Can New Drugs Help Chemotherapy Score Against Cancer?

Bruce Goldman

The first 150 words of the full text of this article appear below.

For the vast stretch of evolutionary time preceding refrigeration, running water, and airtight packaging, life was short and food was dirty. In today’s industrialized world, things are different. But the mechanisms that evolved in living cells to protect them from dangerous substances introduced through ingestion, inhalation, and infection remain intact.

Prominent among these mechanisms is a family of cell-membrane-anchored proteins that act as "goalies" for the cell, denying entry to foreign toxins that would otherwise diffuse through the cell membrane. The first such pump to be identified, P-glycoprotein or simply P-gp, is common in the gut, liver, and kidney—where toxins abound—as well as the testes and blood-brain barrier.

This goalie is ultra-versatile: A variety of structurally diverse chemicals are substrates for P-gp, which makes good evolutionary sense, because there are not enough genes to code for all the pumps that would be required if each were narrowly specific. Unfortunately, many . . . [Full Text of this Article]

Redundant Mechanisms

Old Drugs, New Tricks?

New Drugs, New Trials


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
C. J. Vecht and M. van Breemen
Optimizing therapy of seizures in patients with brain tumors
Neurology, December 26, 2006; 67(12_suppl_4): S10 - S13.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. Teraishi, S. Wu, J. Sasaki, L. Zhang, H.-B. Zhu, J. J. Davis, and B. Fang
P-Glycoprotein-Independent Apoptosis Induction by a Novel Synthetic Compound, MMPT [5-[(4-Methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone]
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 355 - 362.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Mahadevan and A. F. List
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
Blood, October 1, 2004; 104(7): 1940 - 1951.
[Abstract] [Full Text] [PDF]